

The Readout Loud
STAT
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Episodes
Mentioned books

13 snips
Nov 13, 2026 • 20min
421: The future of heart drug research in the wake of study setbacks
Matthew Herper, STAT’s senior medical writer covering medicine, biotech, and drug development, examines why two genetically validated heart drugs failed in major trials. He explores what the setbacks mean for cardiovascular research and funding, whether genetics remains a reliable guide, and where future breakthroughs may emerge. The conversation also covers safety concerns at Vertex and Novartis, plus Alnylam’s growth and reimbursement challenges.

11 snips
Nov 6, 2026 • 30min
420: Democrats’ midterm victory, and a questionable fertility procedure
Daniel Payne, STAT’s Washington correspondent, explores how Democratic midterm gains could reshape drug pricing, Medicaid, NIH independence, and the FDA. Science and health journalist Megan Molteni investigates fertility clinics abroad promoting experimental mitochondrial replacement, or “three-parent IVF,” to women seeking solutions for age-related infertility. The discussion examines fertility tourism, steep costs, limited evidence, and troubling gaps in patient disclosure and oversight.

8 snips
Oct 30, 2026 • 20min
419: Assessing Merck and Moderna's mRNA cancer vaccine
Andrew Joseph, a STAT health and biotech journalist covering cancer research and drug development, joins the conversation on the latest oncology breakthroughs. They explore Merck and Moderna’s personalized mRNA vaccine for melanoma, questions around timing and access, Moderna’s market reaction, a promising small-cell lung cancer combination, and Roche’s advances in KRAS-targeted therapies.

20 snips
Oct 23, 2026 • 35min
418: Remembering STAT’s Helen Branswell
Rick Berke, STAT’s executive editor and veteran health journalist, remembers pioneering infectious disease reporter Helen Branswell. He recounts hiring her, her prescient early COVID warnings, fearless questioning of officials, and evidence-first reporting. Colleagues, family, and public health leaders reflect on her mentorship, credibility, humility, and lasting legacy.

18 snips
Oct 16, 2026 • 20min
417: Hospitals' next lucrative bet — longevity clinics
Sarah Todd, a STAT reporter covering health care and medicine, explores longevity medicine’s multitrillion-dollar boom. She visits Northwestern’s clinic and examines hospitals’ push into cash-pay aging care, pricey testing batteries, biological-age scores, whole-body scans, and personalized lifestyle guidance. The conversation also tackles uncertain evidence, patient risks, and how luxury longevity services could deepen health inequality.

34 snips
Oct 8, 2026 • 34min
416: NIH funding uncertainty thwarts U.S. researchers
Heather Pierce, Association of American Medical Colleges science policy leader, and Anil Oza, STAT’s NIH reporter, unpack turmoil surrounding U.S. biomedical research funding. They discuss political influence, grant delays, career disruptions, and the future of the scientific workforce. The conversation also explores Caribou Biosciences’ closure, optogenetics’ Nobel recognition, gloomy biotech markets, and Boston’s essential movies.

53 snips
Oct 1, 2026 • 31min
415: Mistrust in science and a juicy gene-editing lawsuit
Nicholas Florko, an investigative health journalist at STAT, examines America’s unraveling trust in science. He explores vaccine skepticism, measles, political influence, medical misinformation, and why fact-checking alone falls short. The discussion also covers UniQure’s wavering Huntington’s gene-therapy results, Beam Therapeutics’ trade-secret lawsuit, and pharma’s shift toward lifestyle-focused GLP-1 marketing.

43 snips
Sep 24, 2026 • 30min
The FDA's Overton era, and dispatches from Shanghai
Jason Mast, STAT’s biotech and pharma reporter, joins from Shanghai to explore China’s rise as a drug-development powerhouse, shifting dealmaking, and troubling clinical-trial oversight. Margaret Manto, STAT’s FDA reporter, examines Heidi Overton’s nomination, the agency’s upheaval, and possible policy battles. Plus, osteoporosis returns to biotech’s agenda and Telix’s $1.65 billion ITM acquisition challenges Novartis.

47 snips
Sep 17, 2026 • 28min
Definium's new psychedelics data, and a reprieve for international scientists
Fanta Av, NAFSA’s international education leader, and Jonathan Wosen, a STAT reporter covering biomedical research, discuss a court reprieve for international researchers and the visa uncertainty driving scientists abroad. They explore the stakes for U.S. medical research, Definium’s promising Phase 3 LSD trial for anxiety, Scholar Rock’s muscle-loss treatment, and pharma’s increasingly consumer-focused marketing.

42 snips
Sep 10, 2026 • 31min
Why two promising heart drugs flopped and what's next
Ethan Weiss, a UCSF cardiologist and biotech entrepreneur, examines why two billion-dollar heart drug programs failed. He discusses Lp(a), residual cardiovascular risk, genetic validation, and the future of clinical trials. The conversation also covers FDA approvals, safety transparency, and renewed excitement around personalized cancer vaccines from Merck and Moderna.


